Filing Flows

Filing Flows › 13F managers › Gilead Sciences

Gilead Sciences: 13F portfolio Q2 2026 and what copying it returned

Gilead Sciences' 13F for the quarter ended 2026-06-30 (filed Aug 3, 2026): 5 common-share positions, $1.6B reported. Copying each 13F the day after it was filed returned +70.8% from May 15, 2025 to Nov 6, 2026, against +25.1% for SPY.

Reported 13F assets$1.6B
Positions (common)5
Quarter2026-06-30
Clone return+70.8%
SPY, same days+25.1%
Clone max drawdown-28.4%

Copying the 13F

2025-052025-082025-112026-022026-052026-082026-11cloneSPY

Each 13F bought at the close of the first trading day after it was filed and held, drifting, until the next one; value-weighted over the common-share positions with a price (71.6% of the portfolio on average); 6 filings since May 13, 2025. Price returns for the clone and SPY alike (no dividends, no costs). A 13F lists only US long positions at quarter end, reported up to 45 days later.

Largest holdings (2026-06-30)

Gilead Sciences: largest 13F holdings, 2026-06-30Gilead Sciences: largest 13F holdings, 2026-06-30RCUS · Arcus Biosciences$969MLKFT · Lakefront Biotherapeutics …$500MASMB · Assembly Biosciences$137MKYTX · Kyverna Therapeutics$36.8M
Gilead Sciences: positions grown and trimmed in the quarter (change in shares; new positions and exits are listed below)Gilead Sciences: positions grown and trimmed in the quarter (change in shares; new positions and exits are listed below)ASMB+10%
TickerCompanyWeightValueChange in the quarter
RCUSArcus Biosciences58.8%$969Munchanged
LKFTLakefront Biotherapeutics NV30.3%$500Munchanged
ASMBAssembly Biosciences8.3%$137M+10.5%
KYTXKyverna Therapeutics2.2%$36.8Munchanged

Biggest adds

Biggest cuts

Track record

Of 6 position changes scored in 6 separate decisions, 33.3% were on the right side of SPY over the next three months (Disclosures → Smart money).

Open in Disclosures → every quarter, the clone month by month, the smart-money record

Source: SEC Form 13F-HR, filer CIK 882095. Not investment advice.